Finanzen von Travere Therapeutics Inc (TVTX)TVTXTravere Therapeutics Inc

Travere Therapeutics, Inc. (TVTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is FILSPARI, accounting for 87.4% of total sales, equivalent to $141.08M. Another important revenue stream is Tiopronin Products. Understanding this composition is critical for investors evaluating how TVTX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Travere Therapeutics, Inc. maintains a gross margin of 88.96%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -11.11%, while the net margin is -24.06%. These profitability ratios, combined with a Return on Equity (ROE) of -236.35%, provide a clear picture of how effectively TVTX converts its operational activities into shareholder value.

In the context of the broader market, TVTX competes directly with industry leaders such as ERAS and RGC. With a market capitalization of $5.02B, it holds a significant position in the sector. When comparing efficiency, TVTX's gross margin of 88.96% stands against ERAS's N/A and RGC's N/A. Such benchmarking helps identify whether Travere Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

In Q2 2026, Travere reported total revenue of $169 million, a 48% increase from the previous year, but also a net loss of $34.79 million. The gross margin remains strong at 96.45%.